NellOne Therapeutics is at the forefront of regenerative medicine, focusing on the development of NELL1, a matricellular signaling protein that plays a crucial role in tissue repair and regeneration. NELL1 is naturally expressed during fetal development, a phase characterized by significant regenerative capabilities and scarless healing. The protein functions similarly to a general contractor, orchestrating the repair of damaged soft and hard tissues by directing cellular resources and facilitating the formation of the extracellular matrix (ECM). This biological glue is essential for proper cell orientation and communication, enabling effective tissue restoration and regeneration.

The therapeutic potential of NELL1 extends to various medical conditions, including severe injuries and disorders affecting soft and hard tissues, such as viral-induced lung injuries, osteoporosis, and systemic inflammation. NELL1's multifaceted biological activities include controlling inflammation, recruiting stem cells, forming new blood vessels, and restoring tissue mass and function. By addressing both acute and chronic injuries, NELL1-based treatments aim to enhance patient quality of life while alleviating the burden on healthcare systems through practical and cost-effective solutions.

United States

NellOne Therapeutics is passionate about its work to pioneer advances in the field of tissue regeneration, developed over the course of many years of scientific research and exploration. Our highly experienced team is committed to improving outcomes for millions of patients across the world, and creating a successful business that truly makes a difference.

NellOne Therapeutics

Company Details